Introduction
============

DJ-1 is a causative gene of a familial form of Parkinson's disease (PD), namely *PARK7*, and plays a significant role in antioxidative defense to protect the cells from oxidative stress.^(1--3)^ DJ-1 undergoes preferential oxidation at the cysteine residue at position 106 (Cys-106) under oxidative stress.^([@B4])^ The critical role of Cys-106 in the biological function of DJ-1 has been demonstrated, and recent studies indicate that DJ-1 acts as a sensor of oxidative stress by changing the gene expression levels of antioxidative defense.^([@B2],[@B3],[@B5])^ Specific antibodies against Cys-106-oxidized DJ-1 (oxDJ-1) have been developed, and the generation of oxDJ-1 in cellular and animal models of PD has been investigated.^(6--8)^ This review focuses on the role of DJ-1 in antioxidative defense and the significance of oxidizable Cys-106 in its function (Fig. [1](#F1){ref-type="fig"}). The importance of the identification of PD biomarkers and the nature of oxDJ-1 as a biomarker for PD are discussed here.

Parkinson's Disease and Oxidative Stress
========================================

PD is a progressive, age-related, neurodegenerative disorder that is prevalent worldwide. PD is characterized by bradykinesia, rigidity, tremors, and gait dysfunction with postural instability.^([@B9])^ The pathological hallmark of PD is the degeneration of dopamine neurons in the substantia nigra pars compacta and the subsequent depletion of striatal dopamine.^([@B10])^ Autopsy studies have revealed that a pathological sign of PD is the presence of insoluble clumps of protein, called Lewy bodies, and a characteristic pattern of Lewy bodies in the PD-affected brain has been suggested.^([@B11])^ Although the etiology of PD remains unknown, increasing evidence suggests that oxidative stress is an important mediator in its pathogenesis.^([@B12],[@B13])^ It is thought that nigral dopaminergic neurons are rich in reactive oxygen species (ROS) because the enzymatic and non-enzymatic metabolism of dopamine itself leads to the generation of ROS, including superoxide anions, hydrogen peroxide (H~2~O~2~), and hydroxyl radicals.^(12--14)^ Monoamine oxidase, which is bound to the outer membrane of the mitochondria, catalyzes the oxidation of monoamines including dopamine, and enzymatically generates H~2~O~2~.^([@B14],[@B15])^ Furthermore, dopamine breakdown can occur spontaneously in the presence of iron, resulting in the generation of free radicals.^([@B14])^ In addition, in nigral dopaminergic neurons, calcium entry through L-type channels occurs throughout the pacemaking cycle causing metabolic consumption of ATP, resulting in ROS generation.^([@B16])^ There is abundant evidence, such as the increased levels of the oxidation products of lipids, proteins, and nuclear acids in nigral cells, to imply the role of oxidative stress in PD.^(12--14)^ In addition, materials generating ROS and oxidative stress have been known to increase the risk of PD. Environmental factors including prolonged pesticide exposure, which can cause oxidative stress, have been observed to increase the risk of PD onset.^([@B17])^ Altered levels of heavy metals such as copper and iron have also been found specifically in the substantia nigra of PD patients compared to healthy controls.^([@B18])^ Moreover, a change in antioxidant defense, and decrease in the glutathione (GSH) content of the nigral lesion is known to occur in PD.^([@B19])^ Phospholipid hydroperoxide GSH peroxidase (PH-GPx), which removes lipid hydroperoxide and H~2~O~2~ in the presence of GSH, has also been reported to colocalize with Lewy bodies in the substantia nigra of PD-affected brains.^([@B20])^ Overall, PH-GPx was significantly reduced in the substantia nigra in PD, while higher expression levels of PH-GPx were observed in the surviving nigral cells.^([@B20])^ Collectively, these reports indicate a pivotal role of oxidative stress in the onset and progression of PD. Thus, treatment with antioxidants is expected to slow or prevent the progression of PD, although it has not yet been developed.

Identification of the DJ-1 Gene as *PARK7*
==========================================

Recent genetic studies are yielding new insights into the molecular mechanisms underlying the pathogenesis of PD. In the last two decades, several genetic mutations have been identified that cause familial forms of PD with similar clinical and pathological features to idiopathic PD.^(1--3,21)^ Mutation of α-synuclein has been identified as a causative gene in a familial form of PD, namely *PARK1/4*, and then α-synuclein was found to be the major fibrillar component of Lewy bodies, the pathological hallmark of familial and sporadic PD.^([@B21],[@B22])^ *Parkin* and *PTEN-induced kinase 1* (*PINK1*) have also been identified as *PARK2* and *PARK6*, respectively, and these genes play an important role in the maintenance of mitochondrial function. In 2003, the DJ-1 gene was identified as *PARK7*.^([@B23])^ Mutations in *PARK7* can cause autosomal recessive parkinsonism, and the early onset and slow progression of parkinsonism caused by *PARK7* are similar to those seen in the other recessive PD syndromes, such as parkinsonism caused by *PARK2* and *PARK6*. Several mutations of DJ-1 were found in familial forms of PD, and the point mutations such as L166P and M26I of DJ-1 have been reported to cause its severe destabilization of the DJ-1 protein and the loss of DJ-1 function (Fig. [2](#F2){ref-type="fig"}).^([@B21],[@B23])^ DJ-1 was first identified by Ariga *et al.*^([@B24])^ as an oncogene that cooperates with *ras* in regulating cellular transformation. Therefore, the gain of DJ-1 function is related to cancer (Fig. [2](#F2){ref-type="fig"}). DJ-1 was also found to be a positive regulator of the androgen receptor, and is related to infertility.^([@B25])^ DJ-1 possesses several functions, namely a multifunctional protein, that is involved in various physiological processes such as transcriptional regulation, antioxidative defense, mitochondrial function, and signal transduction.

Protein Characterization of DJ-1
================================

DJ-1 is homodimeric protein with each subunit comprising from 189 amino acids (Fig. [3](#F3){ref-type="fig"}A).^([@B24])^ It is ubiquitously expressed throughout the body. DJ-1 is an abundant cellular protein and has been identified in several proteome studies using two dimensional-polyacrylamide gel electrophoresis (2D-PAGE) with protein staining.^([@B4],[@B26])^ The crystal structure of DJ-1 provided a great insight to this multi-functional protein.^(27--29)^ The DJ-1 monomer takes a flavodoxin-like Rossmann fold, which contains a seven-strand parallel β-sheet as a core (Fig. [3](#F3){ref-type="fig"}B). This β-sheet is sandwiched by α-helices; therefore, the DJ-1 monomer has a three-layered structure. The tertiary structure of DJ-1 is similar to that of the bacterial cysteine protease PH1704, which is a member of the PfpI superfamily,^([@B27],[@B28])^ and DJ-1 belongs to this superfamily. However, DJ-1 has lost a catalytic triad that is essential for protease activity. Furthermore, the putative active site of DJ-1, Cys-106, is masked by an additional C-terminal helix. Several studies have suggested the protease activity of DJ-1; however, this protease activity is very low.^([@B30])^ Both the cleavage of the C-terminal helix under oxidative stress and the increase in the protease activity of the C-terminal helix deletion mutant have been reported.^([@B30])^ However, the physiological role of DJ-1 as a cysteine protease is still under debate. In addition, the tertiary structure of DJ-1 was similar to that of *E. coli* heat shock protein HSP31, a structural homolog of PH1704 protease.^([@B28])^ It is interesting to note that DJ-1 has been reported to act as a redox-activated chaperone.^([@B31],[@B32])^ *E. coli* protein YajL, called as a member of the DJ-1/Hsp31/PfpI superfamily, functions as a covalent chaperones that is involved in the detection of sulfenylated proteins by forming mixed disulfide bonds with them. These disulfides are subsequently reduced by low molecular weight thiols.^([@B32])^ In the case of DJ-1, similar covalent chaperone activity has been discovered. Many DJ-1-interacting proteins have been reported,^([@B33])^ and the chaperone activity of DJ-1 might be responsible for the interactions with some of the identified proteins. Moreover, it has been discovered that HSP31 has glyoxalase activity, converting glyoxal or methylglyoxal to glycolic or lactic acid.^([@B34])^ Similarly, the glyoxalase enzyme activity of DJ-1 has been demonstrated. As expected of a member of the DJ-1/Hsp31/PfpI superfamily, DJ-1 acts as a protease, molecular chaperone, and glyoxalase, and its character might be related to several cellular functions including the regulation of antioxidative defense.

Cys-106 of DJ-1, the postulated active site of the cysteine protease, is structurally close to glutamate 18 (Glu-18), depressing p*K*a value; therefore, Cys-106 is susceptible to oxidation (Fig. [3](#F3){ref-type="fig"}D).^([@B35])^ The point mutation of E18A depresses the pKa of Cys-106 and stabilizes the oxidized form of Cys-106.^([@B35],[@B36])^ The formation of the homodimer is important for the biological activity of DJ-1. The mutations related to the familial form of PD, such as L166P and M26I, destroy the dimer structure of DJ-1 and diminish its biological activity.^([@B21],[@B23],[@B27],[@B28])^ In addition to Cys-106, DJ-1 has two more cysteine residues, namely Cys-53 and Cys-46, which are located at the dimer interface (Fig. [3](#F3){ref-type="fig"}A). Although Cys-106 is the most susceptible to oxidation, these other cysteines are also thought to regulate the function of DJ-1 under oxidative stress.^([@B37])^

Oxidation of DJ-1 and its Antioxidative Function
================================================

A proteomic study of cultured cells using 2D-PAGE revealed that the isoelectric point of DJ-1 showed an acidic mobility shift under oxidative stress.^([@B4],[@B26])^ The structural characterization of an acidic isoform of DJ-1 by using liquid chromatography-mass spectrometry revealed that the cysteines in DJ-1 were oxidized to cysteine sulfonic acid (Cys-SO~3~H) when cells were exposed to H~2~O~2~.^([@B4])^ According to the information about the protein structure, Cys-106 of DJ-1 is preferentially oxidized in cells exposed to oxidative stress. Cys-106 is now accepted to be the key residue involved in the antioxidative action of DJ-1.^([@B2],[@B5])^ Cysteine forms three different oxidized species, namely cysteine-sulfenic acid (Cys-SOH), cysteine-sulfinic acid (Cys-SO~2~H), and Cys-SO~3~H through direct oxygen addition (Fig. [4](#F4){ref-type="fig"}). 2D-PAGE has shown an acidic spot shift of DJ-1 in cells under oxidative stress, and previous studies have shown that these acidic pI shifts are due to a post-translational process induced by the oxidation of the cysteine residue to Cys-SO~2~H or Cys-SO~3~H.^([@B4])^ Cys-SO~2~H is chemically unstable and easily oxidized to Cys-SO~3~H. However, it has been reported that Cys-SO~2~H is stable in oxDJ-1 because of the surrounding amino acid residues.^([@B36])^ The Cys-SO~2~H form of oxDJ-1 is likely to be the active form, and further oxidation to Cys-SO~3~H leads to loss of biological function.^([@B5],[@B31])^ DJ-1 can react with ROS such as H~2~O~2~. However, this reaction is not enzyme-catalyzed,^([@B38])^ and might be less efficient at removing H~2~O~2~ compared with other antioxidative enzymes, such as GPxs, peroxiredoxins, and catalase. In this point of view, it is thought that DJ-1 is not effective antioxidant. Thus, it is reasonable to consider that DJ-1 plays a role in antioxidative defense via oxidation of Cys-106 to regulate transcription factors rather than removing ROS via direct oxidation of Cys-106.

Recent evidence indicates that DJ-1 acts as a sensor of oxidative stress to alter the expression levels of genes involved in antioxidative defense.^([@B2],[@B3],[@B5])^ It has been reported that DJ-1 regulates glutathione metabolism and the expression of heat shock proteins and uncoupling proteins (UCP4 and UCP5).^([@B16],[@B39])^ It has also been reported that DJ-1 stabilizes NF-E2-related factor 2 (Nrf2), the master transcriptional factor of antioxidative defense: DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway.^([@B40])^ Moreover, it has been demonstrated that DJ-1 regulates transcriptional factors p53 in a oxidation-dependent manner.^([@B41])^ These lines of evidence suggest that oxidation physiologically activates DJ-1 to regulate these transcriptional factors related to antioxidative defense.

It has been known that DJ-1 regulates signal transduction related to oxidative stress response and cell death. The phosphoinositide 3-kinase (PI3K)/Akt pathway is the major signaling pathway for cell growth and survival.^([@B42])^ Phosphatase and Tensin homolog deleted from chromosome 10 (PTEN) inhibits PI3K and acts as a negative regulator of the PI3K/Akt pathway.^([@B42],[@B43])^ DJ-1 directly binds to PTEN to inhibit its enzymatic activity: DJ-1 exhibit its cytoprotective action via the promotion of the PI3K/Akt pathway.^([@B44],[@B45])^ DJ-1 also regulates signal transduction of Apoptosis signal-regulating kinase 1 (ASK1) and death domain-associated protein (Daxx).^(37,46)^ ASK1 is a member of mitogen activated protein (MAP) kinase kinase kinase family, and Daxx is associates with ASK1 in the cytoplasm to induce apoptosis under oxidative stress. DJ-1 binds to both ASK1 and Daxx to prevent the association between these signal molecules, thereby inhibiting oxidative stress-induced apoptosis.^(37,46--48)^ In addition, DJ-1 regulates the expression of superoxide dismutase-1 (SOD1) through the extracellular signal-regulated kinases (ERK) pathway, one of MAP kinase signaling pathway.^(49)^ Collectively, DJ-1 exhibits its antioxidative function to prevent oxidative stress-induced cel death by regulating various signaling pathways.

Cellular Function of DJ-1
=========================

DJ-1 is predominantly present in cytoplasm, but also exists in the nucleus and is associated with mitochondria. It has been reported that DJ-1 moves to the nucleus and the mitochondria under oxidative stress, while some mutants of DJ-1, including L166P and M26I, become monomers, and accumulate in the mitochondria.^(50)^ The 12 *N*-terminal amino acids in DJ-1 are necessary for this localization, although DJ-1 has no mitochondrial target sequence. DJ-1 binds to subunits of mitochondrial complex I and regulates its activity.^(51)^

Recent evidences reveals the distinct role of DJ-1 in dopamine metabolism: DJ-1 upregulates the transcription of tyrosine hydroxylase, the rate-limiting enzyme of dopamine synthesis, by inhibiting the SUMOylation of pyrimidine tract binding protein-associated splicing factor (PSF).^(52)^ DJ-1 also activates dopamine synthesis through interaction with dopamine biosynthetic enzymes such as tyrosine hydroxylase and 4-dihydroxy-l-phenylalanine decarboxylase, in an oxidation-dependent manner.^(53)^ These observations suggest the predominant role of DJ-1 in the homeostasis of dopaminergic neurons. Slight oxidative stress inducing DJ-1 oxidation to Cys-106-SOH was found to upregulate dopamine synthesis, while extensive oxidative stress inducing DJ-1 oxidation to Cys-106-SO~2~H or Cys-106-SO~3~H did not upregulate dopamine production.^(53)^ Dopaminergic cells are vulnerable and rich in ROS; therefore, DJ-1 in dopaminergic cells acts as a sensor of oxidative stress, which reflects the levels of dopamine synthesis.

Significance of Biomarker for PD
================================

The identification of a biomarker for PD is vital for overcoming PD, particularly a biomarker for PD in its early phases.^(54)^ Diagnosis of PD is dependent on the cardinal symptoms such as resting tremor, rigidity, and bradykinesia. However, more than half of the dopamine-producing neurons in the substantia nigra have been lost by the time the patient is diagnosed with PD.^([@B9],[@B10])^ Identification of a biomarker for PD in the early phases would have several benefits: researchers could identify preclinical PD patients by this biomarker, and longitudinal studies of preclinical PD patients could help researchers develop a novel drug to slow or prevent the progression of the disease. Besides, the effects of developed treatments will be evaluated by this biomarker for PD in its early phases. Biomarkers provide quantitative information about a living body, not only from body fluids but also from imaging. In the case of PD, several trials using an imaging biomarker have been conducted: changes in dopamine transporters and iron deposition in the substantia nigra have been identified by using imaging techniques such as magnetic resonance imaging (MRI).^(55,56)^ Imaging baiomarkers have also been used to detect the change of peripheral tissues, which has been applied to the diagnosis of PD. ^123^I-meta-iodobenzylguanidine (MIBG) uptake in the myocardium has been used for the evaluation of the sympathetic nerve in the diagnosis of cardiac infarction. In the early phases of PD, cardiac sympathetic dysfunction and reduced cardiac ^123^I-MIBG uptake have been reported.^(57)^ Therefore, ^123^I-MIBG scintillation has been used to evaluate the uptake of this probe in the myocardium, which in turn has been used for the diagnosis of PD. These imaging techniques provide reliable information for the diagnosis of PD. However, analysis using these biomarkers requires specific instruments as well as the administration of the probe. Therefore, there are lots of issues to be resolved before these techniques can be used clinically to predict PD.

Biochemical biomarkers for early-phase PD have been the subject of extensive studies, as with imaging biomarkers. For example, the abnormal oligomeric forms of α-synuclein, a major component of Lewy bodies, have been determined in blood and cerebrospinal fluid (CSF). Higher than normal levels of these oligomeric forms in PD patients have been reported.^(58,59)^ However, a biochemical biomarker for early-phase PD has not yet been developed. The development of a biochemical biomarker for early phase-PD presents some difficulties.^(60)^ PD is complex and can be difficult to diagnose, particularly in its early phases; it can sometimes be misdiagnosed as another diseases such as progressive supranuclear palsy (PSP). Therefore, it appears to be difficult to develop a diagnostic system using a single biomarker. It is important to examine several biomarker candidates, such as imaging and biochemical markers, simultaneously.^(61)^ This strategy has also been tried in the research project known as Parkinson's Progression Markers Initiative of the Michael J. Fox Foundation for PD.^(62)^ The identification of an early-phase PD biomarker might require a large amount of funding, human resources, specialized instruments, and organized effort because researchers would have to evaluate several biomarker candidates in many patients over a long period.

oxDJ-1 as a Possible Biomarker for PD
=====================================

DJ-1 is a promising candidate as a biomarker for PD. The biomarker stduies of DJ-1 in PD were summerized in Table [1](#T1){ref-type="table"}. DJ-1 is induced by oxidative stress: an increase of DJ-1 protein is expected to reflect oxidative stress in PD patients.^(38,[@B63])^ The determination of DJ-1 content in blood and CSF has been studied. However, the results reported by several groups are controversial (Table [1](#T1){ref-type="table"}).^(64--66)^ DJ-1 content in erythrocytes is remarkably high, and hemolysis and contamination by erythrocytes greatly affects the DJ-1 level in plasma and CSF.^(66,67)^ Thus, to determine the DJ-1 content in plasma and CSF, an evaluation of hemolysis and contamination by erythrocytes is necessary. Shi *et al.*^(66)^ has been reported that using plasma without hemolysis, plasma DJ-1 is not useful as biomarkers for PD diagnosis or progression/severity. On the other hand, using CSF without contamination of blood cells, it has been demonstrated that DJ-1 and α-synuclein significantly decreased in PD patients compared with AD patients and control subjects.^(67,[@B68])^ It has also been repported that this change of DJ-1 in CSF does not differentiate among parkinsonian syndromes such as dementia with Lewy body (DLB), PSP, and multiple system atrophy (MSA).^(69)^ Reduced concentrations of amyloid β peptide 1-42 in CSF of AD have been generally accepted.^(70)^ At present, molecular mechanism of decrease in CSF DJ-1 has not been elucidated.

In addition to the quantity of DJ-1, its qualitative change, oxidation, is an interesting candidate for a PD biomarker. To determine oxDJ-1 in biological samples, our research group developed specific antibodies against oxDJ-1 and reported an increase in oxDJ-1 levels in erythrocytes and the brain.^([@B6],[@B7])^ Using a competitive enzyme-linked immunosorbent assay (ELISA) to detect oxDJ-1, it was discovered that the oxDJ-1 levels in the erythrocytes of unmedicated PD patients were markedly higher than those in the erythrocytes of medicated patients (treated with L-DOPA and/or dopamine agonist) or healthy subjects (Fig. [5](#F5){ref-type="fig"}A).^([@B6])^ The term "unmedicated PD patients" refers to patients diagnosed with PD but not yet started on medications such as L-DOPA and/or dopamine agonist. Therefore, unmedicated PD patients are basically those with PD in its early phases. This result suggests that the ELISA system for oxDJ-1 detection is useful for the identification of PD in its early phases. Another group has recently reported the change of 4-hydroxy-2-nonenal-modified DJ-1 in the whole blood of PD patients.^(71)^ In addition to the human study, we have reported that animal models of PD, developed by the administration of neurotoxins such as 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), are subject to the oxidative modification of DJ-1 in the brain and erythrocytes (Fig. [5](#F5){ref-type="fig"}B).^([@B7])^ Based on immunohistochemical analyses of the substantia nigra of MPTP-treated mice, the number of oxDJ-1-positive cells exhibiting astrocyte-like morphology increases depending on the dose of neurotoxins. Collectively, these results suggest that DJ-1 oxidation in erythrocytes and the brain is a common phenomenon in PD patients and animal models of PD. It is not clear whether oxDJ-1 in erythrocytes of PD patients is derived from brain or erythrocytes. However, it is impossible to measure oxDJ-1 levels in human brain at present. The measurement of oxDJ-1 in erythrocyes have several benefits, such as handiness and versatility, as a biomarker of PD.

At present, the biological link between the onset of PD and the alteration of DJ-1 in erythrocytes has not been elucidated. The movement dysfunction associated with PD is considered to be just the tip of the iceberg, and several changes, including the formation of Lewy bodies in the peripheral tissues of PD patients, are known. The substantial relationship between central nerve system and peripheral tissues in PD pathology is still unclear. It is significant to elucidate this relationship not only for the understanding of PD pathology but also for the development of reliable biomarker of PD.

Conclusions
===========

Several studies strongly indicates a relationship between DJ-1 oxidation, oxidative stress, and the onset and progress of PD. The importance of the prevention of oxidative stress in PD is understood. Elucidation of the timing and site of oxidative stress in PD might be required to develop the therapy using antioxidants. Recently, a correlation between oxDJ-1 levels in erythrocytes and MIBG scintillation in PD patients has been discovered. The examination of several PD biomarker candidates might lead to the diagnosis of PD in its early stages.

ASK1

:   apoptosis signal-regulating kinase 1

CSF

:   cerebrospinal fluid

Daxx

:   death domain-associated protein

ELISA

:   enzyme-linked immunosorbent assay

ERK

:   extracellular signal-regulated kinase

GPx

:   glutathione peroxidase

GSH

:   glutathione

HSP

:   heat shock protein

H~2~O~2~

:   hydrogen peroxide

MAPK

:   mitogen activated protein kinase

MIBG

:   meta-iodobenzylguanidine

MPTP

:   1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

MRI

:   magnetic resonance imaging

Nrf2

:   NF-E2-related factor 2

oxDJ-1

:   Cys-106-oxidized DJ-1

PD

:   Parkinson's disease

PH-GPx

:   Phospholipid hydroperoxide glutathione peroxidase

PINK1

:   PTEN-induced kinase 1

PI3K

:   phosphoinositide 3-kinase

PSF

:   pyrimidine tract binding protein-associated splicing factor

PTEN

:   phosphatase and tensin homolog deleted from chromosome 10

ROS

:   reactive oxygen species

SOD1

:   superoxide dismutase-1

SOH

:   sulfenic acid

SO~2~H

:   sulfinic acid

SO~3~H

:   sulfonic acid

TRX

:   thioredoxin

2D-PAGE

:   two-dimensional polyacrylamide gel electrophoresis

UCP

:   uncoupling protein

Conflict of Interest
====================

No potential conflicts of interest were disclosed.
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![Tertiary structure of DJ-1 protein. (A) Gross strucutre of DJ-1 protein. The DJ-1 dimer is shown with one monomer (blue) and the other (red). The three cysteine residues in DJ-1 are also shown. (B) Molecular model of monomer DJ-1. The green tube and brown arrow correspond to α-helix and β-sheet structures, respectively. The figure was made with Cn3D software. (C) The residues composing the environment of Cys-106. The thiol of Cys-106 (C106) makes two direct hydrogen bonds with surrounding atoms (dashed): one to Glu-18 (E18) and the other to an ordered water molecule. (A and C, reference (35); B, reference (28) with permission and modifications).](jcbn13-108f03){#F3}

![Oxidation of cysteine residue in DJ-1. Cys-106 of DJ-1 is sequentially oxidized to SOH, SO~2~H, and SO~3~H.](jcbn13-108f04){#F4}

![Oxidized DJ-1 levels in erythrocytes of PD patients and animal model of PD. (A) The levels of oxidized DJ-1 in erythrocytes of unmedicated PD patients were significantly higher than those in medicated PD patients and healthy subjects (\**p*\<0.01 by ANOVA, Tukey). (B) After the administration of saline (control) and MPTP (15 mg/kg × 1, 2, and 3 i.p.), the levels of oxidized DJ-1 were quantified using a competitive ELISA system. The mean values of oxidized DJ-1 contents per total protein are shown with SD. (*n* = 6--8 in each group). \**p*\<0.01 (Tukey, ANOVA) when compared with control. (A, reference (6); B, reference (7) with permission and modifications).](jcbn13-108f05){#F5}
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Biomarker study of DJ-1 in PD

  Study cited                                    Disease and number\*                                              Material      Method          Outocome reported
  ---------------------------------------------- ----------------------------------------------------------------- ------------- --------------- --------------------------------------------------------------------------------------------
  Neurobiol Aging 2012; 33: 836. e5--e7          LRRK2 (26)                                                        CSF           Luminex assay   DJ-1 in LRRK2 CSF do not correlate with striatal dopaminergic function.
  Parkin Rel Dis 2012; 18: 899--901^(69)^        PD (30), DLB (17), PSP (19), MSA (14), CBD (6), Unspecified (6)   CSF           ELISA           DJ-1 concentration in CSF does not differentiate among parkinsonian syndromes.
  Sci Rep 2012; 2: 954^(71)^                     PD (159), AD (14), Cont (60)                                      Whole blood   2D-PAGE, WB     Blood levels of DJ-1 with 4-HNE modifications were altered in late-stage Parkinson disease
  Ann Neurol 2011; 69: 570--580^(68)^            PD (126), AD (50), MSA (32), Cont (137)                           CSF           Luminex assay   DJ-1 levels were decreased in PD versus Cont or AD.
  Brain 2011; 134: 1--5                          PD (24), Cont (25)                                                Saliva        Luminex assay   DJ-1 increased in PD patients compared to control.
  Neurosci Lett 2010; 480: 78--82^(66)^          PD (126), AD (33), Cont (122)                                     Plasma        Luminex assay   DJ-1 in plasma is not useful as biomarkers for PD diagnosis or progression/severity.
  Brain 2010; 133: 713--726^(67)^                PD (117), AD (50), Cont (132)                                     CSF           Luminex assay   DJ-1 levels were decreased in PD patients versus Cont or AD patients.
  Neurosci Lett 2009; 465: 1--5^([@B6])^         PD (unmedicated, 8; medicated, 7), Cont (18)                      RBC           ELISA           Oxidized DJ-1 of unmedicated PD patients were higher than medicated PD patients and Cont.
  Neurosci Lett 2008; 431: 86--89^(64)^          PD (95), Other Disease (30), Cont (24)                            Serum         ELISA           There was no significant difference between the levels of serum DJ-1 in PD and Cont.
  Neurosci Lett 2007; 425: 18--22^(65)^          PD (104), DLB (30), Cont (80)                                     Plasma        WB              Plasma DJ-1 levels in PD were significantly higher than Cont.
  Biochem Biophys Res Comm 2006; 345: 967--972   PD (40), Cont (38)                                                CSF           WB              The CSF DJ-1 levels in PD were significantly higher than Cont.

\*The number of determined samples was shown in parentheses. LRRK2; leucine-rich repeat kinase 2, CSF; cerebrospinal fluid, PD; Parkinson's disease, DLB; dementia with Lewy body, PSP; progressive supranuclear palsy, MSA; multiple system atrophy, CBD; corticobasal degeneration, ELISA; enzyme-linked immunosorbent assay, AD; Alzheimer's disease, 2D-PAGE; 2 dimensional-polyacrylamide gel electrophoresis, WB; western blot, RBC; red blood cell.
